I, MDD outpatients | II, Hospital personnel | III, Healthy, controls | P -value | ||||
---|---|---|---|---|---|---|---|
Group I vs. II | Group I vs. III | Group II vs. III | All three groups | ||||
Sample size | 534 | 615 | 380 | ||||
Age (year) a, b | 35.99 ± 12.23 | 39.28 ± 11.61 | 35.58 ± 10.86 | 0.000 | 0.885 | 0.000 | 0.000e |
<25 | 116 | 38 | 57 | ||||
25-39 | 217 | 284 | 193 | ||||
40-54 | 147 | 226 | 105 | ||||
55-70 | 54 | 56 | 25 | ||||
>70 | 0 | 11 | 0 | ||||
Sex (M/F) c | 187/347 | 182/433 | 160/220 | 0.049 | 0.030 | 0.000 | |
HDRS score a,d | 20.58 ± 7.00 | 2.2 ± 0.8 | 1.2 ± 1.0 | 0.000 | 0.000 | 0.143 | |
CIC+ (%) c | 97 (18.2%) | 134 (21.8%) | 42 (11.1%) | 0.001 | 0.024 | 0.000 | |
p24 RNA+ (%) c | 27 (5.1%), | 50 (8.1%), | 8 (2.1%), | 0.038 | 0.022 | 0.000 | |
CIC+ and p24 RNA + c | 21 (3.9%), | 48 (7.8%) | 5 (1.3%) | 0.006 | 0.019 | 0.000 | |
CIC+ and/or p24 RNA + c | 103 (19.3%), | 136 (22.1%), | 45 (11.8%), | 0.239 | 0.003 | 0.000 | |
CIC- and p24 RNA+ | 6 | 2 | 3 | ||||
CIC level | 0.197f | ||||||
Negative and borderline | 437 | 454 | 332 | ||||
Weakly/1+ positive | 82 | 134 | 42 | ||||
2+ positive | 14 | 23 | 6 | ||||
3+ and 4+ positive | 1 | 4 | 0 | ||||
Antibody+/CIC+ | 5/50 | 3/50 | 4/40 | ||||
Antibody+/CIC+ | 0/50 | 1/50 | 1/40 |